Lutetium-177 DOTATATE peptide receptor radionuclide therapy — the targeted radioligand delivering beta radiation to somatostatin receptor-expressing neuroendocrine tumors with 65-80% disease control rates and improved progression-free survival, now first-line for advanced gastroenteropancreatic NETs representing the fastest-growing targeted radiotherapy in the global neuroendocrine...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek